

**THOMAS PATRICK AHERN
CURRICULUM VITAE**

Position: Assistant Professor
Department of Surgery

Address: 89 Beaumont Avenue
Given Building, Room D317A
Department of Surgery
The Robert Larner, M.D. College of Medicine
University of Vermont
Burlington, VT 05405
Voice: (802) 656-3690
email: thomas.ahern@med.uvm.edu
website: <http://med.uvm.edu/surgery/bio?BioID=25374>

EDUCATION

<u>Year</u>	<u>Institution</u>	<u>Degree</u>	<u>Area of Degree, Accolades</u>
2012	Harvard School of Public Health	Post-Doctoral	Cancer Epidemiology
2010	Boston University	Ph.D.	Epidemiology
2006	Boston University	M.P.H	Epidemiology
1999	University of Vermont	B.S.	Biochemistry

LICENSES, CERTIFICATION

Years License/Certification

FACULTY POSITIONS HELD

<u>Years</u>	<u>Institution</u>	<u>Academic Title</u>	<u>Department</u>
2013-Present	University of Vermont, Larner College of Medicine	Assistant Professor	Surgery
2012-2013	Brigham and Women's Hospital	Associate Epidemiologist	Medicine
2011-2012	Harvard Medical School	Instructor	Medicine

OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD

<u>Years</u>	<u>Location/Program Name</u>	<u>Role</u>
2012-2013	Department of Clinical Epidemiology, Aarhus University, Denmark	Visiting Fellow

HONORS AND AWARDS *[All inclusive, most recent last]*

Year	Name of Award
2011	Fred F. Kadlubar Scholar-in-Training Award <ul style="list-style-type: none"> • American Association for Cancer Research
2011	Best Presentation by a Postdoctoral Fellow <ul style="list-style-type: none"> • Harvard School of Public Health
2012	Molecular Epidemiology Group Scholar-in-Training Award <ul style="list-style-type: none"> • American Association for Cancer Research
2012, 2014, 2015	Loan Repayment Program, Clinical Research <ul style="list-style-type: none"> • National Institutes of Health
2017	James E. Demeules Award for Dedication to Excellence in Research <ul style="list-style-type: none"> • Department of Surgery, University of Vermont Medical Center
2018	Rising Star New Investigator Award <ul style="list-style-type: none"> • Dean’s Excellence in Research Awards, The Robert Larner, M.D. College of Medicine at The University of Vermont

KEYWORDS/AREAS OF INTEREST

Epidemiology; Molecular Epidemiology; Pharmacoepidemiology; Breast Neoplasms; Medical Oncology
--

SUMMARY OF PROFESSIONAL ACTIVITIES- OVERALL *[optional-needed for promotion and reappointment]* Principle activity (e.g. teaching, research or clinical) *[Focus on activities in last 5 years, but include longer time periods as appropriate. Be concise and limit to 500 words or less.]*

TBD

SUMMARY OF ACCOMPLISHMENTS *Please indicate no more than 8 career accomplishments. Use Single sentences and bullets*

TBD

PROFESSIONAL SERVICE

DEPARTMENTAL SERVICE

<u>Years</u>	<u>Department</u>	<u>Committee</u>	<u>Role</u>
2010-2012	Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School	Channing Happiness Committee	Member
2014-Present	Surgery	Surgical Senior Program Committee	Member
2015-Present	Surgery	Surgical Research Committee	Member

COLLEGE SERVICES

<u>Years</u>	<u>Service Committee</u>	<u>Role</u>
2014	Vermont Cancer Center Research Symposium Planning Committee	Symposium Co-chair (with Professor Chip Cole)
2016-Present	Data Stewardship Committee, Vermont Health Care Uniform Reporting and Evaluation System (VHCURES)	Member

MEDICAL CENTER SERVICE

<u>Years</u>	<u>Service Committee</u>	<u>Role</u>
--------------	--------------------------	-------------

UNIVERSITY SERVICE

<u>Years</u>	<u>Service Committee</u>	<u>Role</u>
2016-Present	University of Vermont Faculty Senate	Elected Senator

GOVERNMENT

<u>Years</u>	<u>Service Committee</u>	<u>Role</u>
--------------	--------------------------	-------------

SOCIETY MEMBERSHIPS

<u>Years</u>	<u>Society</u>
2006-Present	Society for Epidemiologic Research
2009-Present	American Association for Cancer Research
2016-Present	International Society for Pharmacoepidemiology

SERVICE TO PROFESSIONAL ORGANIZATIONS

Years	Service Committee	Role
2014	Abstract Mentoring Committee, Society for Epidemiologic Research	Mentor
2014-2015	Post-Doctoral Grant Review Committee, Susan G. Komen for the Cure	Reviewer
2014	Session Co-chair, Annual Meeting of the Society for Epidemiologic Research, “Modifiable risk factors for breast cancer: still searching...”	Co-chair
2015	Grant Review Committee, Mary Kay Ash Charitable Foundation	Reviewer
2015-2018	Awards Committee, Society for Epidemiologic Research	Member
2016-Present	Abstract Review Committee, Society for Epidemiologic Research	Member
2018-Present	Awards Committee, Society for Epidemiologic Research	Co-chair
2018	Abstract Review Committee, International Society for Pharmacoepidemiology	Member

SERVICE TO PROFESSIONAL PUBLICATIONS

Years	Journal/Publication/Board
Multiple, ongoing	JAMA Oncology, <i>Ad hoc</i> reviewer. Journal of the National Cancer Institute, <i>Ad hoc</i> reviewer. Journal of Clinical Oncology, <i>Ad hoc</i> reviewer. British Medical Journal, <i>Ad hoc</i> reviewer. Epidemiology, <i>Ad hoc</i> reviewer. American Journal of Epidemiology, <i>Ad hoc</i> reviewer. Cancer Causes and Control, <i>Ad hoc</i> reviewer. The Oncologist, <i>Ad hoc</i> reviewer. Pharmacoepidemiology and Drug Safety, <i>Ad hoc</i> reviewer. British Journal of Cancer, <i>Ad hoc</i> reviewer. Canadian Medical Association Journal, <i>Ad hoc</i> reviewer. European Journal of Cancer, <i>Ad hoc</i> reviewer. European Journal of Epidemiology, <i>Ad hoc</i> reviewer. The Breast, <i>Ad hoc</i> reviewer. Preventive Medicine, <i>Ad hoc</i> reviewer. Journal of Clinical Epidemiology, <i>Ad hoc</i> reviewer. Clinical Epidemiology, <i>Ad hoc</i> reviewer. Pediatrics, <i>Ad hoc</i> reviewer. Breast Cancer Research and Treatment, <i>Ad hoc</i> reviewer.

PUBLIC SERVICE

Years	Service Role
1995-2000	Emergency Medical Technician, University of Vermont Rescue Squad

SUMMARY OF SERVICE ACTIVITIES**TEACHING**FORMAL SCHEDULED CLASSES

Year	Course Title	Course R E	Hours	Number of Learners	Level
2012, 2014, 2016, 2018	Analysis, validity, and inference in observational epidemiology, University of Tampere, Finland		x 8 hrs/day 5 days	~20	G

CURRICULUM DEVELOPMENTPOSTGRADUATE AND OTHER COURSES

Years	Department	Responsibility
2016-2018	“Introduction to Clinical Research” Offered to UVM Medical Group physicians. Provides instruction in basic study design and analysis. Facilitates individual research projects using secondary data from the Jeffords Institute for Quality.	Course faculty; responsible for didactic lectures and mentoring/analytic support for student projects

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program School	Role	Current Position
2012	Gitte Vrelits Sørensen, Medical student	Aarhus University	Research year advisor	Attending physician
2015	Rose Leshner, Undergraduate	Honors College University of Vermont	Thesis advisor	Yoga instructor
2016	Simon Ramsdal Sørensen, Medical student	Aarhus University	Research year advisor	Medical student

DISSERTATION/THESIS COMMITTEE MEMBERSHIP

Dates	Name	Program School	Role	Current Position
2016- present	Anne Broe	Clinical Biochemistry and Pharmacology, University of Southern Denmark	Doctoral thesis committee member	Doctoral student
2016- present	Zandra Nymand Ennis	Clinical Biochemistry and Pharmacology,	Doctoral thesis committee	Doctoral student

6. **Ahern TP**, Lash TL, Egan KM, Baron JA. Lifetime tobacco smoke exposure and breast cancer incidence. *Cancer Causes Control* 2009;20:1837-44.
7. **Ahern TP**, Bosco JLF, Silliman RA, et al. Potential misinterpretations caused by collapsing upper categories of comorbidity indices: an illustration from a cohort of older breast cancer survivors. *Clinical Epidemiology* 2009;1:93-100. PMID: PMC2943165.
8. **Ahern TP**, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL. No increase in cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. *Cancer Epidemiol Biomarkers Prev* 2009;18:2562-4. PMID: PMC2742564.
9. Lee JC, **Ahern TP**, Chaves FP, Quillen K. Utility of hematologic and volume, conductivity, and scatter parameters from umbilical cord blood in predicting chorioamnionitis. *Int J Lab Hematol* 2009;32:351-9.
10. Lash TL, Cronin-Fenton D, **Ahern TP**, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton Dutoit S, Garne JP, Ewertz M, Sørensen HT, Pedersen L. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. *Acta Oncol* 2010;49:305-12. PMID: PMC2892037.
11. **Ahern TP**, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT, Lash TL, Hamilton-Dutoit S. Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. *Clinical Epidemiology* 2010;2:241-6. PMID: PMC2998813.
12. Lash TL, Cronin-Fenton DP, **Ahern TP**, et al. CYP2D6 inhibition and breast cancer recurrence in a Danish population-based study. *J Natl Cancer Inst* 2011;103:489-500. PMID: PMC3057982.
13. **Ahern TP**, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL. Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study. *J Natl Cancer Inst* 2011;103:1461-8. PMID: PMC3186780.
14. **Ahern TP**, Pedersen L, Svaerke C, Rothman KJ, Sørensen HT, Lash TL. The association between vitamin K antagonist therapy and site-specific cancer incidence, estimated by using heart valve replacement as an instrumental variable. *Am J Epidemiol* 2011;174:1382-90. PMID: PMC3276295.
15. **Ahern TP**, Christensen M, Cronin-Fenton DP, Lunetta KL, Søiland H, Gjerde J, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors. *Cancer Epidemiol Biomarkers Prev* 2011;20:1937-43. PMID: PMC3169710.
16. Cronin-Fenton DP, Hellberg Y, Lauridsen KL, **Ahern TP**, Garne JP, Rosenberg CL, Silliman RA, Sørensen HT, Lash TL, Hamilton-Dutoit S. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study. *Acta Oncologica*. 2012;51:254-61. PMID: PMC3264781.
17. Lash TL, **Ahern TP**. Bias Analysis to Guide New Data Collection. *Int J Biostat* 2012;8:4679.
18. Sørensen GV, Ganz PA, Cole SW, Pedersen L, Sørensen HT, Cronin-Fenton D, Garne JP, Christiansen P, Lash TL, **Ahern TP**. Use of beta blockers, ACE inhibitors, angiotensin II receptor blockers and risk of breast cancer recurrence: A Danish nationwide prospective cohort study. *J Clin Oncol*. 2013;31:2265-72. PMID: PMC3677839.

19. **Ahern TP**, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM. Plasma c-peptide, mammographic breast density, and risk of invasive breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2013;22:1786-96. PMID: PMC3809910.
20. Cronin-Fenton DP, Christensen M, Lash TL, **Ahern TP**, Pedersen L, Garne JP, Ewertz M, Autrup H, Sørensen HT, Hamilton-Dutoit S. Manganese superoxide dismutase and breast cancer recurrence: A Danish clinical registry-based case-control study, and a meta-analysis. *PLoS ONE.* 2014;9:e87450. PMID: PMC3909115.
21. **Ahern TP**, Tamimi RM, Rosner BA, Hankinson SE. Digoxin use and risk of invasive breast cancer: evidence from the Nurses' Health Study and meta-analysis. *Breast Cancer Res Treat.* 2014;144(2):427-35. PMID: PMC4010120.
22. Lietzen LW, **Ahern TP**, Christiansen PM, Jensen AB, Sørensen HT, Lash TL, Cronin-Fenton DP. Glucocorticoid prescriptions and breast cancer recurrence: A Danish nationwide prospective cohort study. *Ann Oncol.* 2014;25(12):2419-25. PMID: PMC4239807.
23. Cronin-Fenton DP, Heide-Jørgensen U, **Ahern TP**, Lash TL, Christiansen PM, Ejlersen B, Sjøren P, Kehlet H, Sørensen HT. Opioids and breast cancer recurrence: A Danish population-based cohort study. *Cancer.* 2015;121(19):3507-14 PMID: PMC4575607.
24. Cronin-Fenton DP, Sørensen HT, Ejlersen B, Christiansen PM, **Ahern TP**, Lash TL, Heide-Jørgensen U. Low-dose aspirin, non-steroidal anti-inflammatory drugs, selective COX-2 inhibitors and breast cancer recurrence. *Epidemiology.* 2016;27(4):586-93. PMID: PMC5541136.
25. Borgquist S, Tamimi RM, Chen WY, Garber JE, Eliassen AH, **Ahern TP**. Statins and breast cancer risk in the Nurses' Health Study. *Cancer Epidemiol Biomarkers Prev.* 2016;25(1):201-6. PMID: PMC4842011.
26. **Ahern TP**, Cronin-Fenton DP, Lash TL, Sørensen HT, Ording AO, Hamilton-Dutoit SJ, Helberg Y. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study. *Acta Oncol.* 2016;55(6):734-41. PMID: PMC4943575.
27. **Ahern TP**, Hertz DL, Damkier P, Ejlersen B, Hamilton-Dutoit SJ, Rae JM, Regan MM, Thompson AM, Lash TL, Cronin-Fenton DP. Cytochrome P-450 2D6 (CYP2D6) genotype and breast cancer recurrence in tamoxifen-treated patients: evaluating the importance of loss-of-heterozygosity. *Am J Epidemiol.* 2017;185(2):75-85. PMID: PMC5253974.
28. **Ahern TP**, Beck AH, Rosner BA, Glass B, Frieling G, Collins LC, Tamimi RM. Continuous measurement of breast tumor hormone receptor expression: a comparison of two computational pathology platforms. *J Clin Pathol.* 2017;70:428-34. PMID: PMC5763511.
29. Lash TL, Riis AH, Ostfeld EB, Erichsen R, Vyberg M, **Ahern TP**, Thorlacius-Ussing O. Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. *Am J Epidemiol.* 2017 Sep 15;186(6):679-687. PMID: 28338891
30. Borgquist S, Giobbie-Hurder A, **Ahern TP**, Garber J, Colleoni M, Lang I, Debled M, Ejlersen B, von Moos R, Smith I, Coates A, Goldhirsch A, Rabaglio M, Price K, Gelber R, Regan M, Thuerlimann B. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. *J Clin Oncol.* 2017;35(11):1179-90.
31. Broe A, Ennis ZN, Pottgård A, Hallas J, **Ahern TP**, Damkier P. Population Exposure to Phthalate-Containing Drugs. *Basic Clin Pharmacol Toxicol.* Sep;121(3):153-158.2017 PMID: 28371296
32. **Ahern TP**, Sprague BL, Bissell MCS, Miglioretti DL, Buist DSM, Braithwaite D,

- Kerlikowske K. Family history of breast cancer, breast density, and breast cancer risk in a U.S. breast cancer screening population. *Cancer Epidemiol Biomarkers Prev*. 2017;26(6):938-44. PMID: PMC5457358.
33. Cronin-Fenton DP, Kjærsgaard A, **Ahern TP**, Mele M, Ewertz M, Hamilton-Dutoit S, Christiansen P, Ejlersen B, Sørensen HT, Lash TL, Silliman RA. Validity of Danish Breast Cancer Group (DBCG) registry data used in the Predictors of Breast Cancer Recurrence (ProBeCaRe) premenopausal breast cancer cohort study. *Acta Oncol*. Sep;56(9):1155-1160 2017.
 34. Klebaner D, Hamilton-Dutoit S, **Ahern T**, Crawford A, Jakobsen T, Cronin-Fenton DP, Damkier P, Janssen E, Kjaersgaard A, Ording AG, Søiland H, Sorensen HT, Lash TL, Hellberg Y. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients. *PLoS One*. 2017;12(3):e0171453. PMID: PMC5354362.
 35. Damkier P, Kjaersgaard A, Barker KA, Cronin-Fenton DP, Crawford A, Hellberg Y, Janssen EAM, Langefeld C, **Ahern TP**, Lash TL. CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset. *Sci Reports* 2017;7(1):7727. PMID: PMC5552748.
 36. Farina NH, Ramsey JE, Sands ME, **Ahern TP**, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME. Development of a predictive miRNA signature for breast cancer risk among high-risk women. *Oncotarget*. 2017;8(68):112170-112183. PMID: PMC5762501.
 37. Broe A, Pottegård A, Hallas J, **Ahern TP**, Fedder J, Damkier P. Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction. *Hum Reprod*. 2018 [Epub ahead of print] PMID: 29425332
 38. Ennis ZN, Broe A, Pottegård A, **Ahern TP**, Hallas J, Damkier P. Cumulative exposure to phthalates from phthalate-containing drug products: a Danish population-wide study. *British J Clin Pharmacol*. 2018;84(8):1798-1805. PMID: PMC6046487
 39. Fujii MH, Hodges AC, Russell RL, Roensch K, Beynon B, **Ahern TP**, Holoch P, Moore JS, Ames SE, MacLean CD. Post-discharge opioid prescribing and use following common surgical procedures. *J Am Coll Surg*. 2018;226(6):1004-12 PMID: PMC5971152
 40. **Ahern TP**, Veres K, Jiang T, Farkas DK, Lash TL, Sørensen HT, Gradus JL. Adjustment disorder and type-specific cancer incidence: a Danish cohort study. *Acta Oncol*. 2018 [Epub ahead of print] PMID: 29688114
 41. Pottegård A, Lash TL, Cronin-Fenton DP, Ahern TP, Damkier P. Use of antipsychotics and risk of breast cancer: a Danish nationwide case-control study. *Br J Clin Pharmacol*. 2018;84(9):2152-61 PMID: 29858518
 42. Collin LJ, Cronin-Fenton DP, **Ahern TP**, Christensen KB, Damkier P, Hamilton-Dutoit S, Kjaersgaard A, Lauridsen KL, Yacoub R, Christiansen P, Sørensen HT, Lash TL. Expression of survivin does not appear to influence breast cancer recurrence risk. *Acta Oncol*. 2018 [In press]
 43. Colton I, Fujii M, **Ahern TP**, MacLean C, Lahiri J, Alef M, Stanley A, Steinthorsson G, Bertges D. Postoperative Opioid Prescribing Patterns and Use after Vascular Surgery. *Vasc Med*. [In press]
 44. Collin LJ, Cronin-Fenton DP, **Ahern TP**, Christiansen PM, Damkier P, Ejlersen B, Hamilton-Dutoit S, Kjærsgaard A, Silliman RA, Sørensen HT, Lash TL. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRe) Premenopausal Breast Cancer Cohort Study in Denmark. *BMJ Open*. 2018;8(7):e021805. PMID: 30068618 PMID: PMC6074634.

45. Paine AN, Krompf BL, Borrazzo EC, **Ahern TP**, Malhotra AK, Norotsky MC, Tsai MH. The Impact of an Acute Care Surgery Model on General Surgery Service Productivity. Peroperative Care and Operating Room Management. 2018;[In press]

In Review

1. **Ahern TP**, Broe A, Lash TL, Cronin-Fenton DP, Ulrichsen SP, Christiansen PM, Cole BF, Tamimi RM, Sørensen HT, Damkier P. Phthalate exposure and breast cancer incidence: a Danish nationwide cohort study.

In Preparation

1. **Ahern TP**, Damkier P, Kjaersgaard A, Sørensen HT, Hamilton-Dutoit S, Ejlersen B, Christiansen P, Silliman RA, Lash TL, Cronin-Fenton DP. Impact of co-medications on tamoxifen effectiveness in premenopausal breast cancer patients: a study from the Danish population-based ProBe CaRe cohort.

Review Articles

1. **Ahern TP**, Lash TL, Damkier P, Christiansen PM, Cronin-Fenton DP. Statins and breast cancer prognosis: evidence and opportunities. *Lancet Oncol.* 2014;15:e461-8. PMID: PMC4167822.
2. Borgquist S, Bjarnadottir O, Kimbung S, **Ahern TP**. Statins: a role in breast cancer therapy? *J Intern Med.* 2018;284(4):346-57. PMID: 29923256

Books and Chapters

1. **Ahern TP**. Pharmacoepidemiology in Pharmacogenetics. In: *Advances in Pharmacology*, volume 83. Damkier P and Brøsen K (eds.)

Non-Peer Reviewed Publications

Letters

1. Lash TL, **Ahern TP**, Cronin-Fenton D, Garne JP, Hamilton-Dutoit S, Sørensen HT. Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'. *Cancer Sci* 2008;99:1706-7.
2. Lash TL, **Ahern TP**, Cronin-Fenton D. Modification of tamoxifen response: what have we learned? *J Clin Oncol* 2008;26:1764-5; author reply 1765-6.
3. **Ahern TP**, Hankinson SE. Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. *J Natl Cancer Inst* 2011;103:1558-9.
4. Sørensen GV, Cronin-Fenton DP, Sørensen HT, Damkier P, Ejlersen B, Christiansen PM, Lash TL, **Ahern TP**. Re: Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer. *Epidemiology.* 2018 [Epub ahead of print] PMID: 29771735
5. **Ahern TP**, Borgquist S, Cronin-Fenton DP. Re: Association of statin use with overall and cancer survival. *JAMA Oncol.* 2018;4(7)1015-16 PMID: 29800042

Thesis

1. Ahern TP. Estimating the Impact of Molecular Profiles and Prescription Drugs on Breast Cancer Outcomes [dissertation]. Boston (MA): Boston University; 2010.

Abstracts

Patents Issued or Pending

Other Creative Activities**Quality Improvement and Patient Safety Activities**SUMMARY OF SCHOLARLY ACTIVITIES

@@@

INVITED PRESENTATIONS**Regional**

<u>Years</u>	<u>Host Organization</u>	<u>City, State</u>
2008	Boston University School of Public Health, Research in Progress Seminar; Department of Epidemiology. "Cardiac Glycosides and Breast Cancer."	Boston, MA
2011	Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School. "Associations of Plasma Insulin and C-peptide Levels with Mammographic Breast Density and Breast Cancer Risk"	Boston, MA
2011	Harvard School of Public Health Department of Epidemiology, Cancer Epidemiology Fellows' Meeting. "Statin Use and Breast Cancer Recurrence: A Danish Nationwide Prospective Cohort Study."	Boston, MA
2011	Dana-Farber/Harvard Cancer Center Programs in Breast and Gynecologic Cancer, Joint Symposium. "Estimating the Association between Vitamin K Antagonist Therapy and Site-Specific Cancer Incidence Using Heart Valve Replacement as an Instrumental Variable."	Boston, MA
2012	Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Molecular Pathology Working Group Seminar. "Quantitative Measurement of Breast Tumor Biomarkers in the Nurses' Health Study."	Boston, MA
2013	University of Vermont College of Medicine Department of Pharmacology Seminar. "Pharmacoepidemiology studies using the Danish national health registries: examples and opportunities."	Burlington, VT
2014	University of Vermont, Vermont Cancer Center, Cancer Control and Population Health Sciences Program Meeting. "Validation linked with probabilistic bias analysis in a study of anticoagulants and cancer incidence."	Burlington, VT
2014	Vermont Breast Cancer Conference (Keynote Address). "Looking for Avoidable Causes of Breast Cancer: No Trivial Pursuit!"	Burlington, VT
2014	Vermont Breast Cancer Conference. "Phthalates are	Burlington, VT

2016 Everywhere—But Do They Cause Breast Cancer?”
University of Vermont Larner College of Medicine
Department of Biochemistry, Cancer Research and
Technology Seminar. “Molecular Mechanisms of
Tamoxifen Resistance.” Burlington, VT

**National
Years**

Host Organization

City, State

2011	American Association for Cancer Research; Annual Meeting, “Post-diagnosis use of lipophilic statins and breast cancer recurrence: A Danish nationwide cohort study.” Poster presentation.	Orlando, FL
2011	Congressionally Directed Medical Research Programs; Era of Hope Meeting, “Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.” Poster presentation.	Orlando, FL
2011	American Association for Cancer Research; Frontiers in Cancer Prevention Research, “C-peptide, mammographic density, and risk of invasive breast cancer.” Poster presentation.	Boston, MA
2014	American Association for Cancer Research; Frontiers in Cancer Prevention Research, “Digoxin use and risk of invasive breast cancer: evidence from the Nurses’ Health Study.” Poster presentation.	National Harbor, MD
2014	Society for Epidemiologic Research; Annual Meeting, “Breast tumor Pak1 expression, adjuvant tamoxifen therapy, and recurrence risk: a Danish population-based study.” Poster presentation.	Seattle, WA
2014	Society for Epidemiologic Research; Annual Meeting, “Vitamin K antagonist drugs and cancer risk: validation of heart valve replacement as a drug exposure proxy.” Invited talk.	Seattle, WA
2015	Departmental Research Seminar; Department of Epidemiology and Biostatistics, University of Massachusetts, “How to Do Environmental Epidemiology If You Are Locked in a Pharmacy: Drugs, Phthalates, and Breast Cancer Risk.” Invited talk.	Amherst, MA
2015	Northeastern Breast Cancer Research Conference, Norris Cotton Cancer Center, Dartmouth University, “Breast Cancer Pharmacoepidemiology in the Danish National Cohort.” Invited talk.	Lebanon, NH
2015	San Antonio Breast Cancer Symposium, “Statins and breast cancer risk in the Nurses’ Health Study.” Platform and poster discussion.	San Antonio, TX
2015	San Antonio Breast Cancer Symposium, “CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: an evaluation of the importance of	San Antonio, TX

6/7/2018

Thomas Patrick Ahern

2016	loss-of-heterozygosity.” Poster presentation. Society for Epidemiologic Research, Annual Meeting, “Continuous measurement of breast tumor hormone receptor expression: a comparison of two computational pathology platforms.” Poster presentation.	Miami, FL
2017	Society for Epidemiologic Research, Annual Meeting, “Drug interactions with tamoxifen in a Danish premenopausal breast cancer cohort.” Invited talk.	Seattle, WA
2018	Society for Epidemiologic Research, Annual Meeting, “Bayesian meta-analysis and visual examination of assumptions via an online app.” Invited talk.	Baltimore, MD
2018	Society for Epidemiologic Research, Annual Meeting, “Breast cancer risk in chronic users of phthalate-containing medications: A Danish nationwide cohort study.” Poster presentation.	Baltimore, MD
2018	Emory University/Winship Cancer Institute Cancer Control and Population Health Sciences Grand Rounds. “Breast cancer risk in users of phthalate-containing medications: A Danish nationwide cohort study”	Atlanta, GA
International Years	Host Organization	City, Country
2010	Aarhus University Hospital Department of Clinical Epidemiology, “The potential role of p21-activated kinase 1 in tamoxifen resistance.	Aarhus, Denmark
2013	University of South Denmark Department of Clinical Biochemistry and Pharmacology, “Breast cancer risk in chronic users of phthalate-containing medications.”	Odense, Denmark
2014	SOLA Investigators’ Meeting, “Predictive biomarkers of simvastatin effectiveness in the breast cancer adjuvant setting.” Invited talk.	Stavanger, Norway
2017	Lund University, “Statins and breast cancer: current evidence and potential pathways.” Invited talk.	Lund, Sweden
2017	International Conference on Pharmacoepidemiology and Therapeutic Risk Management, “Drug interactions with tamoxifen in a Danish premenopausal breast cancer cohort.” Spotlight poster presentation.	Montréal, Canada
2018	International Conference on Pharmacoepidemiology and Therapeutic Risk Management, “Breast cancer risk in chronic users of phthalate-containing medications: a Danish nationwide cohort study.” Invited talk.	Prague, Czech Republic
2018	International Conference on Pharmacoepidemiology and Therapeutic Risk Management, “Use of antipsychotics and risk of breast cancer.” Spotlight	Prague, Czech Republic

poster presentation.